Previous close | 161.03 |
Open | 157.06 |
Bid | 156.78 x 1000 |
Ask | 156.91 x 900 |
Day's range | 155.31 - 159.67 |
52-week range | 117.08 - 464.00 |
Volume | |
Avg. volume | 1,283,976 |
Market cap | 38.255B |
Beta (5Y monthly) | -0.70 |
PE ratio (TTM) | 5.00 |
EPS (TTM) | 31.54 |
Earnings date | 09 Nov 2021 |
Forward dividend & yield | 2.11 (1.33%) |
Ex-dividend date | 02 Jun 2022 |
1y target est | 320.42 |
Pfizer (NYSE: PFE) is already the leader in the coronavirus vaccine space. Rival Moderna (NASDAQ: MRNA) has a significant position in the market. Latecomer Novavax (NASDAQ: NVAX) could also take market share in the months to come.
The team behind Britain’s most-used Covid booster vaccine is being sued by a German pharmaceutical firm which has accused it of stealing the technology behind the jab.
BERLIN (Reuters) -CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus. The German-based biotech company is seeking "fair compensation" from BioNTech and two subsidiaries for infringement of its intellectual property rights, it said on Tuesday. When asked in a media call, Chief Executive Franz-Werner Haas did not rule out further legal action against BioNTech partner Pfizer or mRNA vaccine maker Moderna.